U.S. License Holder:
Sarepta Therapeutics
Date of License:
June-22-2023
Last Update:
Apr-15-2024
FDA-Approved Indications
ELEVIDYS (delandistrogene moxeparvovec-rokl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.